This app represents an update of the Spanish “Antiretroviral Resistance Guidelines: update 2018”, taking into account the latest data available for the interpretation of resistance to the most used drugs for the treatment of HIV infection including the latest incorporations to the drug pipeline. During the last year, new drugs were approved for the treatment of HIV infection such as the non-nucleoside reverse transcriptase (NNRTI) inhibitor Doravirine and the integrase inhibitor (INI) Bictegravir. The aim of the APP is to be a practical and useful guide to be used in clinical practice. A detailed description of the rules is available at https://www.redris.es/documents/20143/151217/AntiretroviralResistanceGuidelines_RIS_01172019.pdf/72106e34-1ea6-f96e-2605-164d01d1f7a5